abstract |
The composition of the present invention is directed to a composition comprising a 5-alpha reductase inhibitor, wherein said composition is capable of forming liquid crystals upon contact with an aqueous fluid such that the 5-alpha reductase inhibitor continuously releases the drug continuously over a prolonged period of time And the safety of the composition can be improved by remarkably alleviating the stimulation reaction upon administration of the 5-alpha reductase inhibitor. |